LL MD Reports Lyme Disease, Babesiosis, Bartonella Infection, Increase DVT & Blood Clot Risk

Bottom Line

Babesiosis has the clearest biologic and clinical connection to abnormal coagulation, particularly during severe infection, because it can produce hemolysis, endothelial injury, systemic inflammation, disseminated intravascular coagulation (DIC), organ failure, hospitalization, and splenic complications.[1–5]
Bartonella species infect endothelial cells and can cause vasoproliferative disease or endocarditis, but direct evidence that ordinary Bartonella infection commonly causes leg DVT is limited.[6–9]
Lyme disease is not an established common cause of DVT. Published thrombotic events are unusual and generally involve severe inflammation, immobility, cardiac complications, transient autoimmune coagulation abnormalities, or treatment-related intravenous catheters rather than a proven direct effect of Borrelia burgdorferi.[10–12]
In all three conditions, a clot may instead result from ordinary factors such as age, cancer, inherited thrombophilia, estrogen, pregnancy, obesity, surgery, immobility, prior DVT, smoking, or an intravenous line.

“Possible” mechanisms below range from well-supported pathways to rare or theoretical ones. They should not be interpreted as proof that an infection caused an individual patient’s clot.

Potential Pathways

1. Acute Systemic Inflammation Activating Coagulation

Serious infections release inflammatory cytokines such as interleukin-6 and tumor-necrosis factor. These can:

Increase tissue-factor activity
Increase thrombin generation
Activate platelets
Reduce natural anticoagulant pathways
Suppress fibrinolysis
Promote fibrin formation

This infection-associated immunothrombosis is well established generally and is most relevant to severe babesiosis, Bartonella endocarditis, or another systemic infection—not uncomplicated localized Lyme disease.[13–15]

2. Endothelial-Cell Activation or Injury

Inflamed vascular endothelium becomes more adhesive and procoagulant by:

Increasing adhesion molecules
Releasing von Willebrand factor
Recruiting platelets and leukocytes
Expressing tissue factor
Reducing thrombomodulin and other anticoagulant activity

This pathway is particularly biologically plausible in Bartonella, because these organisms have tropism for endothelial cells. Nevertheless, endothelial tropism does not by itself establish that Bartonella commonly causes DVT.[6–8]

Babesia-associated inflammation and hemolysis may also activate or injure the endothelium.[1–5]

3. Babesia-Induced Red-Cell Destruction

Babesia organisms infect red blood cells and can cause substantial intravascular hemolysis. Hemolysis may encourage thrombosis through:

Release of cell-free hemoglobin
Scavenging of nitric oxide
Vasoconstriction and endothelial dysfunction
Release of red-cell membrane particles
Platelet activation
Increased tissue-factor activity
Exposure of procoagulant phospholipids

These mechanisms are established across hemolytic disorders, although the exact contribution to DVT in babesiosis has not been quantified precisely.[1–5,16–17]

4. Disseminated Intravascular Coagulation in Severe Babesiosis

Severe babesiosis can produce DIC, in which widespread coagulation activation consumes platelets and clotting factors. DIC may cause:

Bleeding
Microvascular thrombosis
Organ ischemia
Occasionally clinically apparent larger-vessel thrombosis

A falling platelet count does not necessarily protect against clots; thrombosis and bleeding can occur simultaneously during DIC.[1–5,14–15]

5. Platelet Activation Despite Thrombocytopenia

Babesiosis frequently produces thrombocytopenia. The remaining platelets may nevertheless be activated by:

Systemic inflammation
Endothelial injury
Hemolysis
Thrombin production
Splenic and immune effects

Therefore, a low platelet count does not completely exclude DVT or pulmonary embolism.

6. Neutrophil Extracellular Traps

Activated neutrophils may release DNA-protein webs called neutrophil extracellular traps, or NETs. NETs can:

Provide a scaffold for clot formation
Activate coagulation factors
Trap platelets and red cells
Inhibit normal clot breakdown

This is a recognized mechanism in infection-associated thrombosis generally. Direct organism-specific evidence in Lyme disease, babesiosis, and Bartonella infection remains limited.[13–15]

7. Reduced Fibrinolysis

Inflammation can increase plasminogen activator inhibitor-1 and related mediators, reducing the body’s ability to dissolve fibrin. A clot can therefore:

Form more readily
Persist longer
Propagate within a vein

This is another general severe-infection pathway rather than evidence of a unique Lyme-associated coagulation disorder.[13–15]

8. Dehydration and Hemoconcentration

Fever, sweating, vomiting, diarrhea, poor oral intake, or prolonged illness can cause dehydration. This may:

Concentrate blood components
Reduce venous flow
Worsen hypotension and endothelial stress
Compound other DVT risk factors

Dehydration alone rarely explains a major DVT, but it may contribute during severe babesiosis or another febrile illness.

9. Immobility and Venous Stasis

Pain, fatigue, hospitalization, weakness, neurologic symptoms, or cardiorespiratory illness can substantially reduce mobility. Venous stasis is one component of Virchow’s triad:

Venous stasis
Endothelial injury
Hypercoagulability

This may be more important than any organism-specific effect, especially during prolonged bed rest or hospitalization.[18–19]

10. Intensive-Care Illness and Invasive Procedures

Severe babesiosis can require intensive care, transfusion, exchange transfusion, dialysis, mechanical ventilation, or vasopressor treatment. Critical illness increases thrombosis risk through:

Immobility
Central venous catheters
Systemic inflammation
Organ failure
Vascular injury
Interruption of preventive anticoagulation because of bleeding or low platelets

11. Central or Peripheral Intravenous Catheters

Patients receiving prolonged intravenous antibiotics may develop catheter-associated upper-extremity DVT. This can occur with:

Peripherally inserted central catheters
Central venous catheters
Repeated endothelial trauma
Catheter-associated infection
Reduced blood flow around the catheter

In a Lyme patient, a catheter-related clot is more appropriately attributed to the line and associated risk factors—not automatically to Lyme disease itself. Prolonged IV antibiotics are not recommended for persistent nonspecific symptoms without evidence of active infection.[10–12,20]

12. Splenectomy or Loss of Splenic Function

People without a spleen are at elevated risk for severe babesiosis. Splenectomy is also associated with an increased risk of venous thromboembolism in some populations.

Possible reasons include:

Persistent thrombocytosis
Increased circulating abnormal red-cell material
Reduced clearance of procoagulant microparticles
Altered endothelial and immune function
Greater severity of babesiosis

The infection and the prior splenectomy may therefore act together, but the underlying indication for splenectomy may also affect the risk.[1–5,21]

13. Splenic Infarction or Severe Splenic Inflammation

Babesiosis can produce splenomegaly, splenic infarction, or splenic rupture. Infarction indicates disturbed vascular flow or thrombosis in the splenic circulation but is not the same as leg DVT.

Severe splenic disease may nevertheless signal:

Marked inflammation
Abnormal blood-cell clearance
Significant parasite burden
A broader prothrombotic state

Sudden left-upper-abdominal pain, left shoulder pain, dizziness, or fainting requires emergency assessment.

14. Antiphospholipid Antibodies or Lupus Anticoagulant

Infections can sometimes induce transient antiphospholipid antibodies, including:

Lupus anticoagulant
Anticardiolipin antibodies
Anti-β2-glycoprotein-I antibodies

Some infection-associated antibodies may contribute to thrombosis, but many are temporary and clinically insignificant. A positive test during acute infection does not automatically establish antiphospholipid syndrome.

Definite antiphospholipid syndrome requires an appropriate clinical event plus persistently positive, criteria-level laboratory testing—generally repeated at least 12 weeks later.[22–24] Robust evidence that Lyme disease, Babesia, or Bartonella commonly causes true antiphospholipid syndrome is lacking.

15. Autoimmune Hemolytic Anemia

Babesiosis can occasionally be followed by warm autoimmune hemolytic anemia, particularly after antimicrobial treatment or in patients with altered splenic function. Autoimmune hemolytic anemia itself has been associated with increased venous-thromboembolism risk through:

Ongoing hemolysis
Complement activation
Inflammation
Glucocorticoid treatment
Hospitalization and immobility

This is uncommon but clinically important.[25–27]

16. Complement Activation

Complement can interact with:

Platelets
Endothelial cells
Tissue factor
Neutrophils
Red-cell destruction

Excess complement activation during hemolytic or severe infectious illness may therefore amplify coagulation. This is biologically plausible in severe babesiosis and autoimmune hemolysis but is not proven as an independent cause of most Babesia-associated DVTs.[15–17]

17. Bartonella-Associated Endocarditis

Several Bartonella species can cause culture-negative infective endocarditis. Endocarditis may produce:

Strong systemic inflammatory activation
Endothelial and valvular injury
Immobility and hospitalization
Heart failure
Renal immune-complex disease
Septic emboli

However, vegetations usually cause arterial emboli—such as cerebral, splenic, renal, or limb emboli—not classic venous DVT. A person can still develop DVT secondarily from hospitalization, inflammation, central lines, or other conventional factors.[8–9,28–29]

18. Bartonella-Related Vascular Proliferative Disease

In immunocompromised patients, Bartonella henselae or Bartonella quintana may cause bacillary angiomatosis or peliosis. The organisms promote endothelial proliferation and abnormal vascular lesions.

Potential prothrombotic contributors include:

Local endothelial disruption
Intense inflammation
Abnormal vascular architecture
Serious systemic illness
Immobility

Direct evidence linking these conditions specifically to ordinary lower-extremity DVT remains sparse.[6–8]

19. Cardiac Dysfunction

Rare Lyme manifestations include carditis with high-degree atrioventricular block or myocardial involvement. Bartonella endocarditis and severe babesiosis may also compromise cardiovascular function.

Severe cardiac illness can indirectly encourage thrombosis through:

Hospitalization and immobility
Low-flow states
Central venous access
Heart failure
Systemic inflammation

Intracardiac or arterial embolic events should not be mislabeled as DVT.[8–12]

20. Kidney Injury and Nephrotic-Range Protein Loss

Severe babesiosis may cause acute kidney injury. Bartonella endocarditis can cause immune-complex glomerulonephritis, and rare renal complications have been reported with Lyme disease.

If renal disease produces substantial urinary protein loss or nephrotic syndrome, clotting risk can increase because of:

Urinary loss of antithrombin and other anticoagulant proteins
Increased hepatic synthesis of clotting factors
Platelet activation
Hemoconcentration
Edema-associated venous stasis

This is an uncommon, indirect route rather than a typical feature of Lyme or Bartonella infection.[29–31]

21. Liver Dysfunction and Severe Systemic Illness

Severe infection can disturb hepatic production and clearance of:

Clotting factors
Natural anticoagulants
Fibrinolytic proteins

Liver dysfunction can create a complicated “rebalanced” state in which both bleeding and thrombosis are possible. Standard clotting tests alone may not predict which will occur.

22. Surgery or Invasive Management of Complications

Surgery for splenic rupture, infected tissue, cardiac-valve disease, or another complication adds familiar DVT risks:

Tissue injury
Immobilization
Postoperative inflammation
Central lines
Temporary interruption of anticoagulants
Transfusion and critical illness

The surgery and hospitalization may be stronger causal factors than the original organism.

23. Coinfection Producing More Severe Illness

Coinfection—particularly Lyme disease plus babesiosis—may produce more severe or prolonged illness than Lyme disease alone in some patients. More severe illness can indirectly increase DVT risk through:

Greater inflammation
Longer inactivity
More dehydration
Hospitalization
Catheter placement
Organ dysfunction

Coinfection does not automatically prove the cause of a clot, and each infection should be confirmed using guideline-supported testing.[1–3,10–12]

24. Interaction With Pre-Existing Thrombosis Risks

An infection may act as a “second hit” in someone who already has:

Prior DVT or pulmonary embolism
Factor V Leiden
Prothrombin G20210A variant
Antithrombin, protein C, or protein S deficiency
Active cancer
Pregnancy or postpartum status
Estrogen-containing contraception or hormone therapy
Obesity
Advanced age
Smoking
Recent surgery or trauma
Chronic inflammatory disease

In this setting, even a modest inflammatory illness might help trigger a clot without being the sole cause.

How Strong Is the Evidence?

Infection	Evidence for Coagulation Abnormalities	Evidence for Ordinary Leg DVT
Babesiosis	Strong for hemolysis, thrombocytopenia, severe inflammation and occasional DIC	DVT/PE can occur, especially in severe illness, but incidence is not well defined
Bartonella	Strong for endothelial tropism; established cause of endocarditis and vascular lesions	Direct DVT association is limited; many events are arterial emboli or secondary to severe illness
Lyme disease	Systemic inflammation is possible; rare cardiac, neurologic, renal, or autoimmune complications occur	No established common causal association; evidence consists largely of uncommon reports and indirect pathways

What Clinicians May Evaluate When DVT Occurs

Evaluation is individualized but may include:

Compression ultrasound for suspected limb DVT
CT pulmonary angiography or other testing for suspected pulmonary embolism
Complete blood count and platelet count
Blood smear, bilirubin, LDH, haptoglobin and reticulocyte count when hemolysis is suspected
Kidney and liver tests
PT/INR, aPTT, fibrinogen and D-dimer when DIC is possible
Guideline-supported Babesia smear or PCR testing
Appropriate Lyme serology using validated two-tier testing
Bartonella testing when the clinical syndrome supports it, especially culture-negative endocarditis
Blood cultures and echocardiography when endocarditis is suspected
Urinalysis and urine protein measurement if renal disease is possible
Review of medications, hormones, IV lines, recent surgery, immobility and cancer risk
Selective thrombophilia or antiphospholipid testing when results would change management

A positive Lyme or Bartonella antibody test may reflect past exposure, cross-reactivity, or a false-positive result and does not by itself establish active infection or explain a DVT.

When to Obtain Urgent Help

Call emergency services for:

Sudden shortness of breath
Chest pain, particularly pain worse with breathing
Coughing blood
Fainting, confusion, blue lips, or severe weakness
Rapid heartbeat with breathing difficulty

Obtain prompt medical evaluation for:

New one-sided leg or arm swelling
Limb pain, warmth, redness, or discoloration
Swelling or pain around a PICC or central line

Do not massage a potentially thrombosed limb or self-treat a suspected DVT with aspirin, supplements, antibiotics, or leftover anticoagulants.

Full References

1. Krause PJ. Human babesiosis. International Journal for Parasitology. 2019;49(2):165–174. doi:10.1016/j.ijpara.2018.11.007.

2. Krause PJ, Auwaerter PG, Bannuru RR, et al. Clinical practice guidelines by the Infectious Diseases Society of America: 2020 guideline on diagnosis and management of babesiosis. Clinical Infectious Diseases. 2021;72(2):e49–e64. doi:10.1093/cid/ciaa1216.

3. Vannier E, Krause PJ. Human babesiosis. New England Journal of Medicine. 2012;366(25):2397–2407. doi:10.1056/NEJMra1202018.

4. White DJ, Talarico J, Chang HG, Birkhead GS, Heimberger T, Morse DL. Human babesiosis in New York State: Review of 139 hospitalized cases and analysis of prognostic factors. Archives of Internal Medicine. 1998;158(19):2149–2154. doi:10.1001/archinte.158.19.2149.

5. Hatcher JC, Greenberg PD, Antique J, Jimenez-Lucho VE. Severe babesiosis in Long Island: Review of 34 cases and their complications. Clinical Infectious Diseases. 2001;32(8):1117–1125. doi:10.1086/319742.

6. Dehio C. Bartonella-host-cell interactions and vascular tumour formation. Nature Reviews Microbiology. 2005;3(8):621–631. doi:10.1038/nrmicro1209.

7. Harms A, Dehio C. Intruders below the radar: Molecular pathogenesis of Bartonella spp. Clinical Microbiology Reviews. 2012;25(1):42–78. doi:10.1128/CMR.05009-11.

8. Breitschwerdt EB. Bartonellosis, one health and all creatures great and small. Veterinary Dermatology. 2017;28(1):96-e21. doi:10.1111/vde.12413.

9. Edouard S, Nabet C, Lepidi H, Fournier PE, Raoult D. Bartonella, a common cause of endocarditis: A report on 106 cases and review. Journal of Clinical Microbiology. 2015;53(3):824–829. doi:10.1128/JCM.02827-14.

10. Lantos PM, Rumbaugh J, Bockenstedt LK, et al. Clinical practice guidelines by the IDSA, AAN, and ACR: 2020 guidelines for prevention, diagnosis and treatment of Lyme disease. Neurology. 2021;96(6):262–273. doi:10.1212/WNL.0000000000011151.

11. Steere AC, Strle F, Wormser GP, et al. Lyme borreliosis. Nature Reviews Disease Primers. 2016;2:16090. doi:10.1038/nrdp.2016.90.

12. Marques AR. Lyme disease: A review. Current Allergy and Asthma Reports. 2010;10(1):13–20. doi:10.1007/s11882-009-0077-3.

13. Engelmann B, Massberg S. Thrombosis as an intravascular effector of innate immunity. Nature Reviews Immunology. 2013;13(1):34–45. doi:10.1038/nri3345.

14. Iba T, Levy JH, Warkentin TE, Thachil J, van der Poll T, Levi M. Diagnosis and management of sepsis-induced coagulopathy and disseminated intravascular coagulation. Journal of Thrombosis and Haemostasis. 2019;17(11):1989–1994. doi:10.1111/jth.14578.

15. Levi M, van der Poll T. Coagulation and sepsis. Thrombosis Research. 2017;149:38–44. doi:10.1016/j.thromres.2016.11.007.

16. Rother RP, Bell L, Hillmen P, Gladwin MT. The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin: A novel mechanism of human disease. JAMA. 2005;293(13):1653–1662. doi:10.1001/jama.293.13.1653.

17. Ataga KI, Key NS. Hypercoagulability in sickle cell disease: New approaches to an old problem. Hematology American Society of Hematology Education Program. 2007:91–96. doi:10.1182/asheducation-2007.1.91.

18. Smeeth L, Cook C, Thomas S, Hall AJ, Hubbard R, Vallance P. Risk of deep vein thrombosis and pulmonary embolism after acute infection in a community setting. Lancet. 2006;367(9516):1075–1079. doi:10.1016/S0140-6736(06)68474-2.

19. Heit JA, Spencer FA, White RH. The epidemiology of venous thromboembolism. Journal of Thrombosis and Thrombolysis. 2016;41(1):3–14. doi:10.1007/s11239-015-1311-6.

20. Chopra V, Anand S, Hickner A, et al. Risk of venous thromboembolism associated with peripherally inserted central catheters: A systematic review and meta-analysis. Lancet. 2013;382(9889):311–325. doi:10.1016/S0140-6736(13)60592-9.

21. Boyle S, White RH, Brunson A, Wun T. Splenectomy and the incidence of venous thromboembolism and sepsis in patients with immune thrombocytopenia. Blood. 2013;121(23):4782–4790. doi:10.1182/blood-2012-12-467068.

22. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome. Journal of Thrombosis and Haemostasis. 2006;4(2):295–306. doi:10.1111/j.1538-7836.2006.01753.x.

23. Barbhaiya M, Zuily S, Naden R, et al. The 2023 ACR/EULAR antiphospholipid syndrome classification criteria. Arthritis & Rheumatology. 2023;75(10):1687–1702. doi:10.1002/art.42624.

24. Abdel-Wahab N, Talathi S, Lopez-Olivo MA, Suarez-Almazor ME. Risk of developing antiphospholipid antibodies following viral infection: A systematic review and meta-analysis. Lupus. 2018;27(4):572–583. doi:10.1177/0961203317731532.

25. Raffalli J, Wormser GP. Persistence of babesiosis for >2 years in a patient on rituximab for rheumatoid arthritis. Diagnostic Microbiology and Infectious Disease. 2016;85(2):231–232. doi:10.1016/j.diagmicrobio.2016.02.016.

26. Narurkar R, Mamorska-Dyga A, Nelson JC, Liu D. Autoimmune hemolytic anemia associated with babesiosis. Biomarker Research. 2017;5:14. doi:10.1186/s40364-017-0095-6.

27. Audia S, Bach B, Samson M, et al. Venous thromboembolic events during warm autoimmune hemolytic anemia. PLoS ONE. 2018;13(11):e0207218. doi:10.1371/journal.pone.0207218.

28. Fournier PE, Thuny F, Richet H, et al. Comprehensive diagnostic strategy for blood culture-negative endocarditis: A prospective study of 819 new cases. Clinical Infectious Diseases. 2010;51(2):131–140. doi:10.1086/653675.

29. Raybould JE, Raybould AL, Morales MK, et al. Bartonella endocarditis and pauci-immune glomerulonephritis: A case report and review of the literature. Infectious Diseases in Clinical Practice. 2016;24(5):254–260.

30. Kerlin BA, Ayoob R, Smoyer WE. Epidemiology and pathophysiology of nephrotic syndrome-associated thromboembolic disease. Clinical Journal of the American Society of Nephrology. 2012;7(3):513–520. doi:10.2215/CJN.10131011.

31. Mahmoodi BK, ten Kate MK, Waanders F, et al. High absolute risks and predictors of venous and arterial thromboembolic events in patients with nephrotic syndrome. Circulation. 2008;117(2):224–230. doi:10.1161/CIRCULATIONAHA.107.716951.